Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: Enigma, wrapped in mystery, enclosed in conundrum

Annals of Neurology

Volumn 66, Issue 3, 2009, Pages 259-261

  Ransohoff, Richard M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; NATALIZUMAB;

BLOOD BRAIN BARRIER; BRAIN BIOPSY; DEMYELINATION; EDITORIAL; HUMAN; IMMUNOCOMPETENCE; IN SITU HYBRIDIZATION; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENCE RISK; RISK BENEFIT ANALYSIS;

ADULT; ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 70350061599     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21850     Document Type: Editorial

References (16)

1. Schweikert A, Kremer M, Ringel F, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 2009;66:403-407.
2. Bhagavathi S, Wilson JD. Primary central nervous system lymphoma. Arch Pathol Lab Med 2008;132:1830-1834.
3. Deangelis LM, Wong E, Rosenblum M, et al. Epstein-Barr virus in acquired immune deficiency syndrome (AIDS) and non- AIDS primary central nervous system lymphoma. Cancer 1992; 70:1607-1611.
4. Nakamura M, Shimada K, Ishida E, et al. Histopathology, pathogenesis and molecular genetics in primary central nervous system lymphomas. Histol Histopathol 2004;19:211-219. (Pubitemid 38111265)
5. Brunn A, Montesinos-Rongen M, Strack A, et al. Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma. Acta Neuropathol 2007;114: 271-276. (Pubitemid 47226153)
6. Alderson L, Fetell MR, Sisti M, et al. Sentinel lesions of primary CNS lymphoma. J Neurol Neurosurg Psychiatry 1996;60: 102-105. (Pubitemid 26012277)
7. Deangelis LM. Primary central nervous system lymphoma imitates multiple sclerosis. J Neurooncol 1990;9:177-181. (Pubitemid 20319398)
8. Ng S, Butzkueven H, Kalnins R, et al. Prolonged interval between sentinel pseudotumoral demyelination and development of primary CNS lymphoma. J Clin Neurosci 2007;14: 1126-1129. (Pubitemid 47588932)
9. Brecher K, Hochberg FH, Louis DN, et al. Case report of unusual leukoencephalopathy preceding primary CNS lymphoma. J Neurol Neurosurg Psychiatry 1998;65:917-920. (Pubitemid 128710435)
10. Hochberg FH, Baehring JM, Hochberg EP. Primary CNS lymphoma. Nat Clin Pract Neurol 2007;3:24-35.
11. Poser CM, Brinar VV. Epilepsy and multiple sclerosis. Epilepsy Behav 2003;4:6-12.
12. Herrlinger U, Schabet M, Bitzer M, et al. Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neurooncol 1999;43:219-226. (Pubitemid 29488378)
13. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007;356:2622-2629.
14. Zecca C, Nessi F, Bernasconi E, Gobbi C. Ocular toxoplasmosis during natalizumab treatment. Neurology 73: ePub September 23, 2009.
15. Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 2008;358:647-648. (Pubitemid 351214309)
16. Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-747. (Pubitemid 43673151)